RxDoctor Payments Data

Nidia Colomer de Saca, MD

Psychiatry · Chino, CANPI 1790880854

Payments from drug & device makers

$6,021in general payments, 2019–2025

Across 322 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$847
  • Teva Pharmaceuticals USA, Inc.$786
  • Neurocrine Biosciences, Inc.$644
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$301
  • Alkermes, Inc.$210
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$5,78196%
  • Education$2394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,021 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$103,036
Medicare patients
162
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine13$64,573
Lurasidone Hcl156$45,638
Abilify MaintenaAripiprazole13$41,793
FanaptIloperidone14$38,197
VraylarCariprazine Hcl14$24,845
CaplytaLumateperone Tosylate12$18,998
Aripiprazole162$15,980
AbilifyAripiprazole12$12,049
Ambien CrZolpidem Tartrate12$7,612
Quetiapine Fumarate320$6,901
Clozapine77$5,902
InvegaPaliperidone11$5,878
Fluphenazine Hcl12$5,538
LexaproEscitalopram Oxalate12$4,971
SeroquelQuetiapine Fumarate13$4,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$786$64,57313 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$847$41,79313 claims
Vanda Pharmaceuticals Inc.Fanapt$46$38,19714 claims
AbbVieVraylar, Lexapro$2,160$29,81626 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$301$18,99812 claims
E.r. Squibb & Sons, L.L.C.Abilify$144$12,04912 claims
Johnson & JohnsonInvega$183$5,87811 claims
Lilly USA, LLCOlanzapine$23$1,642120 claims
Almatica Pharma LLCSertraline Hcl$70$997177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →